About 200 reports

gastrointestinal, central nervous system, and hormonal therapies).

  • Leukemia
  • Alcon, Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • HEMATOLOGICAL CANCERS THERAPEUTICS MARKET, GLOBAL, APPROVED INDICATIONS FOR
  • HEMATOLOGICAL CANCERS THERAPEUTICS MARKET, GLOBAL, APPROVED INDICATIONS FOR

It is also in development within the gastrointestinal disease area.

  • Leukemia
  • World
  • Market Size
  • Celgene Corporation
  • Novartis AG

OVERALL, ##% AND ##% OF PATIENTS WITH AML REQUIRED DOSE ADJUSTMENT DUE TO GASTROINTESTINAL OR HEMATOLOGIC AES, RESPECTIVELY (SAVONA ET AL., 2014).

  • Leukemia
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.
  • Celgene Corporation
  • Novartis AG
  • Leukemia
  • AbbVie Inc.
  • Amgen Inc.
  • Biogen Idec Inc.
  • Bristol-Myers Squibb Company

It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

  • Leukemia
  • China
  • Trade
  • Lijun Pharmaceutical Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • GLEEVEC DRUG PROFILE
  • Leukemia
  • Amgen Inc.
  • ARIAD Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.

It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

  • Leukemia
  • China
  • Demand
  • Market Size
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd

They have sixty plus products on market, covering categories of gastrointestinal, cardiovascular, anti-tumor, and antibiotics. - Haitian International Trading Co., Ltd.

  • Leukemia
  • China
  • Supply
  • Zhejiang Expressway Co., Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • MERCK & CO., INC.
  • June 12, 2015

FINDINGS: May ##, 2015 ## Among these subgroup of subjects, more common grade ## or higher non-hematologic adverse events in the vosaroxin combination arm include gastrointestinal and myelosuppression-related toxicities, consistent with those observed in previous company studies.

  • Blood Disease
  • Clinical Trial
  • Leukemia
  • United States
  • World

FRONTIER PHARMA First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline Published: May 2017 Report Code: GBIHC##MR www. gbiresearch. com © GBI Research.

  • Leukemia
  • World
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Novartis AG
  • PRESS RELEASE 4

Most common adverse events were grade ##-## and gastrointestinal in nature.

  • Leukemia
  • Japan
  • Demand
  • Celgene Corporation
  • Nippon Shinyaku Co., Ltd.

They have sixty plus products on market, covering categories of gastrointestinal, cardiovascular, anti-tumor, and antibiotics. - Haitian International Trading Co., Ltd.

  • Leukemia
  • China
  • Nanjing Aosaikang Medicinal Group
  • Zhejiang Expressway Co., Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.

OTHER PRODUCTS ARE IN DEVELOPMENT IN RESPIRATORY CONDITIONS, BACTERIAL INFECTIONS, CNS/ PAIN, AND GASTROINTESTINAL DYSFUNCTION.

  • Leukemia
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

The most common co-morbidities in these patients were: gastrointestinal (##-##%) musculoskeletal (##-##%) cardiovascular (##-##%) respiratory (##-##%) dermatologic (##%) hepatobiliary (##-##%) hyperlipidemia (##-##%) diabetes mellitus (##-##%) renal (##-##%). endocrine-metabolic (excluding diabete

  • Leukemia
  • Europe
  • ARIAD Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.

The most frequent AEs reported in the AML patients were gastrointestinal; diarrhea and nausea were observed in five out of the nine AML patients (##%).

  • Leukemia
  • Astellas Pharma Inc.
  • Celator Pharmaceuticals, Inc.
  • Celgene Corporation
  • Novartis AG

THE MOST FREQUENT ADVERSE EVENTS REPORTED WERE ASTHENIA AND GASTROINTESTINAL DISORDERS. ## PERCENT (EIGHT OUT OF ## PATIENTS) SHOWED AN OBJECTIVE RESPONSE INCLUDING THREE WHO SHOWED COMPLETE REMISSION.

  • Leukemia
  • United States
  • Amgen Inc.
  • MedImmune, LLC
  • Novartis AG

THE MAIN TARGET INDICATIONS INCLUDE OVARIAN, BREAST, LUNG AND GASTROINTESTINAL TUMORS.

  • Leukemia
  • New Caledonia
  • MedImmune, LLC
  • Roche Group
  • Xencor, Inc.

IN ADDITION, THE STUDY SHOWED THIS ADC HAS MANAGEABLE NEUTROPENIA AND GASTROINTESTINAL TOXICITIES.

  • Leukemia
  • United States
  • AbbVie Inc.
  • Roche Group
  • Seattle Genetics, Inc.
  • Tasigna: Orphan Drug Designation
  • Leukemia
  • United States
  • ARIAD Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • GASTROINTESTINAL STROMAL TUMOR (GIST) - PIPELINE BY OMEROS CORPORATION, H2 2016
  • GASTROINTESTINAL STROMAL TUMOR (GIST) - PIPELINE BY ARIAD PHARMACEUTICALS, INC., H2...
  • Leukemia
  • Pharmaceutical
  • United States
  • Product Initiative
  • Novartis AG
  • PIPELINE BY CHIPSCREEN BIOSCIENCES LTD, H2 2017
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017

Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Lung Cancer, Metastatic Breast Cancer, Non-Hodgkin Lymphoma, Peripheral T- Cell Lymphomas (PTCL), Peritoneal Cancer, Prostate Cancer, Refractory Acute Myeloid L

  • Leukemia
  • United States
  • World
  • Product Initiative
  • Sareum Holdings plc
  • Clinical Trial profile. 159 Trial Title
  • Clinical Trial profile. 45 Trial Title

Proportion of Oral Mucositis to Gastrointestinal Clinical Trials, E## Countries (%), 2016* In total there were ## clinical trials conducted on Oral Mucositis, as of September 2016 in E## Countries, of these ## clinical trials were in India.

  • Hospital
  • Leukemia
  • World
  • Product Initiative
  • Amgen Inc.
  • Sareum Holdings Plc - Pipeline by Indication, 2016

Key Facts Sareum Holdings Plc, Key Facts Key Therapeutic Areas Sareum Holdings Plc - Research and Development Overview Sareum Holdings Plc has promising clinical drug candidates for ## major therapeutic areas, Central Nervous System, Gastrointestinal, Oncology and Immunology.

  • Cancer
  • Leukemia
  • Pathology
  • World
  • Sareum Holdings plc
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • 4SC-202 - DRUG PROFILE

Common toxicities were hematological and gastrointestinal.

  • Cancer
  • Leukemia
  • United States
  • World
  • Product Initiative
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2017
  • KARYOPHARM THERAPEUTICS INC

We anticipate that this regimen will continue to show reduced rates of cytopenias, neuropathy and gastrointestinal side effects based on the continuing STOMP results.

  • Leukemia
  • Lymphoma
  • United States
  • World
  • Karyopharm Therapeutics Inc.
  • nilotinib - Drug Profile

In April 2007, Novartis was granted orphan drug designation by the US FDA for nilotinib for the treatment of gastrointestinal stromal tumors and later the designation was withdrawn.

  • Leukemia
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.
  • Leukemia
  • Pharmaceutical
  • United States
  • Company
  • Bellicum Pharmaceuticals, Inc.
  • DCC-2618 - DRUG PROFILE
  • ALLAKOS INC.

The most commonly observed side effects on both studies were gastrointestinal toxicity (nausea and vomiting) and transaminase elevations.

  • Dermatological Condition
  • Leukemia
  • Therapy
  • United States
  • Product Initiative
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • RUXOLITINIB PHOSPHATE - DRUG PROFILE

There were no cases of tuberculosis or gastrointestinal perforations.

  • Digestive System Disorder
  • Leukemia
  • Pharmaceutical
  • Therapy
  • Incyte Corporation
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY THERAPY AREA, H2 2016
  • Hospital
  • Leukemia
  • Europe
  • World
  • Product Initiative